Physician
Trusted Doctors LLC
Trusted Doctors LLC was paid $13.54M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 40% of everything it billed.
33Billing provider infoTRUSTED DOCTORS LLC
FAIRFAX, VA 22033
FAIRFAX, VA 22033
33aNPI1083793525assigned 11/03/2006
33bProvider typePediatrics Physician
28Total paid$13.54M
24GClaims427,743
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Virginia
Rank by total paid#3 of 817
Median peer was paid$29K
This provider vs. median462×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,906 | $1.02M | |
| 2019 | 39,026 | $980K | |
| 2020 | 38,690 | $1.05M | |
| 2021 | 62,082 | $2.00M | |
| 2022 | 58,553 | $2.47M | |
| 2023 | 99,919 | $3.30M | |
| 2024incomplete | 103,567 | $2.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 40% | 59,768 | 54,238 | $5.35M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 31% | 61,416 | 55,975 | $4.16M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.3% | 8,817 | 8,160 | $717K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.2% | 7,533 | 6,390 | $568K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.9% | 6,466 | 6,168 | $533K |
| 90686 | 2.0% | 18,191 | 16,140 | $268K | |
| 0240U | 1.9% | 2,110 | 2,072 | $255K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.6% | 2,394 | 2,235 | $215K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 4,266 | 4,131 | $145K |
| 96160 | <1% | 47,645 | 44,853 | $129K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 10,762 | 9,923 | $127K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,710 | 8,569 | $116K |
80 more codes
| 96127 | <1% | 20,731 | $103K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,625 | $96K |
| 90670 | <1% | 3,657 | $84K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 38,993 | $79K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,285 | $66K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,207 | $40K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,914 | $33K |
| 90698 | <1% | 1,756 | $29K | |
| 90461 | <1% | 10,844 | $28K | |
| 90656 | <1% | 1,658 | $28K | |
| 90651 | <1% | 556 | $28K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 794 | $27K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 176 | $22K |
| 99460 | <1% | 226 | $20K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 290 | $20K |
| 90619 | <1% | 183 | $18K | |
| 90680 | <1% | 1,114 | $18K | |
| 99173 | <1% | 6,719 | $16K | |
| 90677 | <1% | 144 | $15K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 119 | $15K |
| 0002A | <1% | 415 | $15K | |
| 0001A | <1% | 444 | $15K | |
| 99000 | <1% | 12,567 | $12K | |
| 99177 | <1% | 2,639 | $11K | |
| 96161 | <1% | 3,017 | $7K | |
| 0071A | <1% | 179 | $7K | |
| 90633 | <1% | 497 | $7K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 55 | $7K |
| 99051 | <1% | 1,490 | $6K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 832 | $6K |
| 90697 | <1% | 154 | $6K | |
| 0072A | <1% | 127 | $5K | |
| 90685 | <1% | 454 | $5K | |
| 90744 | <1% | 379 | $5K | |
| 87807 | <1% | 351 | $5K | |
| 92551 | <1% | 432 | $4K | |
| 88738 | <1% | 1,025 | $4K | |
| 90688 | <1% | 331 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 90 | $3K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 715 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 64 | $3K |
| 90734 | <1% | 117 | $3K | |
| 85018 | <1% | 1,187 | $3K | |
| 97803 | <1% | 168 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 219 | $2K |
| 92567 | <1% | 151 | $2K | |
| 87428 | <1% | 80 | $2K | |
| 99050 | <1% | 137 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 135 | $2K |
| 90648 | <1% | 77 | $1K | |
| 90480 | <1% | 45 | $1K | |
| 90715 | <1% | 53 | $970.24 | |
| 92587 | <1% | 90 | $932.76 | |
| 0081A | <1% | 25 | $906.13 | |
| 99188 | <1% | 51 | $881.05 | |
| 90621 | <1% | 12 | $593.55 | |
| 99072 | <1% | 4,824 | $555.01 | |
| 90723 | <1% | 28 | $535.44 | |
| 0082A | <1% | 22 | $490.71 | |
| 92558 | <1% | 1,646 | $438.05 | |
| 94760 | <1% | 372 | $417.11 | |
| 90674 | <1% | 16 | $373.04 | |
| 36416 | <1% | 4,282 | $231.65 | |
| G9920 | Screening performed and negative | <1% | 28,206 | $225.68 |
| 90700 | <1% | 12 | $155.20 | |
| 90710 | <1% | 13 | $144.10 | |
| 90696 | <1% | 12 | $133.10 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 98 | $108.18 |
| 83655 | <1% | 13 | $93.81 | |
| 87070 | <1% | 19 | $67.68 | |
| 87081 | <1% | 24 | $50.80 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 5,520 | $42.77 |
| 36415 | Collection of venous blood by venipuncture | <1% | 14 | $23.10 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 41 | $2.70 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 444 | $1.67 |
| H0049 | Alcohol and/or drug screening | <1% | 764 | $0.01 |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 1,276 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 30 | $0.00 |
| 3008F | 0% | 3,638 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 556 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTERRY, SHERRYL (ADMINISTRATOR)